Figure 3.

The increase of DAT levels is associated with the G2019S mutation but not sustained by ongoing LRRK2 kinase activity. (A) Western blot analysis of DAT levels in the striatum of 12-month-old G2019S KI, LRRK2 KO and KD mice in comparison with WT controls, and representative blots. Data are means ± SEM of n = 6 mice per group * p < 0.05 different from WT (one-way ANOVA followed by the Tukey test). (B) Kinetic analysis of [³H]-DA uptake in striatal synaptosomes of 12-month-old G2019S KI and WT mice acutely treated with MLi-2 (10 mg/Kg i.p.) or vehicle. Data are expressed as mean ± SEM of n = 4 mice per group. (C,D) Western blot analysis of pSer1292 LRRK2 and total LRRK2 levels in the striatum of G2019S KI mice administered with MLi-2 (10 mg/Kg, i.p.) or vehicle, and representative blots. Data are expressed as mean ± SEM of n = 5 mice per group. ** p < 0.01 different from Vehicle (Student t-test two-tailed, for unpaired data).